SG11202110164YA - Cd28 t cell cultures, compositions, and methods of using thereof - Google Patents
Cd28 t cell cultures, compositions, and methods of using thereofInfo
- Publication number
- SG11202110164YA SG11202110164YA SG11202110164YA SG11202110164YA SG11202110164YA SG 11202110164Y A SG11202110164Y A SG 11202110164YA SG 11202110164Y A SG11202110164Y A SG 11202110164YA SG 11202110164Y A SG11202110164Y A SG 11202110164YA SG 11202110164Y A SG11202110164Y A SG 11202110164YA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- methods
- cell cultures
- cultures
- cell
- Prior art date
Links
- 101150100936 CD28 gene Proteins 0.000 title 1
- 238000004113 cell culture Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/505—CD4; CD8
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962820442P | 2019-03-19 | 2019-03-19 | |
DE102019108125.4A DE102019108125B4 (en) | 2019-03-28 | 2019-03-28 | CD28 T-CELL CULTURES, COMPOSITIONS AND METHODS OF USE |
PCT/US2020/023585 WO2020191172A1 (en) | 2019-03-19 | 2020-03-19 | Cd28 t cell cultures, compositions, and methods of using thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202110164YA true SG11202110164YA (en) | 2021-10-28 |
Family
ID=72612243
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202110164YA SG11202110164YA (en) | 2019-03-19 | 2020-03-19 | Cd28 t cell cultures, compositions, and methods of using thereof |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP3941487B1 (en) |
JP (1) | JP2022526298A (en) |
KR (1) | KR20210141599A (en) |
CN (1) | CN113727721A (en) |
AU (1) | AU2020241411A1 (en) |
CA (1) | CA3133989A1 (en) |
DE (1) | DE102019108125B4 (en) |
MX (1) | MX2021011375A (en) |
SG (1) | SG11202110164YA (en) |
TW (1) | TW202043465A (en) |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
WO2000023573A2 (en) | 1998-10-20 | 2000-04-27 | City Of Hope | Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies |
US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
GB201604494D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers |
GB201604492D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers |
DE102016115246C5 (en) | 2016-08-17 | 2018-12-20 | Immatics Biotechnologies Gmbh | NEW T-CELL RECEPTORS AND THEIR USE IN IMMUNOTHERAPY |
DE102016121899A1 (en) | 2016-11-15 | 2018-05-17 | Immatics Biotechnologies Gmbh | Process for the preparation of electrocompetent yeast cells and methods of using these cells |
DE102016123859B3 (en) | 2016-12-08 | 2018-03-01 | Immatics Biotechnologies Gmbh | New T cell receptors and their use in immunotherapy |
DE102016123893A1 (en) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T cell receptors with improved binding |
DE102016123847B3 (en) | 2016-12-08 | 2018-04-05 | Immatics Biotechnologies Gmbh | New T cell receptors and their use in immunotherapy |
CN110234756A (en) | 2017-01-18 | 2019-09-13 | F1肿瘤医学公司 | The method and application thereof of transduction and amplification immunocyte |
US11236145B2 (en) | 2017-03-23 | 2022-02-01 | Immatics Biotechnologies Gmbh | T cell receptors and immune therapy using the same against PRAME positive cancers |
DE102017114737A1 (en) | 2017-06-30 | 2019-01-03 | Immatics Biotechnologies Gmbh | New T cell receptors and their use in immunotherapy |
-
2019
- 2019-03-28 DE DE102019108125.4A patent/DE102019108125B4/en active Active
-
2020
- 2020-03-18 TW TW109108977A patent/TW202043465A/en unknown
- 2020-03-19 AU AU2020241411A patent/AU2020241411A1/en not_active Withdrawn
- 2020-03-19 KR KR1020217033533A patent/KR20210141599A/en unknown
- 2020-03-19 EP EP20718095.1A patent/EP3941487B1/en active Active
- 2020-03-19 CN CN202080029963.8A patent/CN113727721A/en active Pending
- 2020-03-19 MX MX2021011375A patent/MX2021011375A/en unknown
- 2020-03-19 JP JP2021556499A patent/JP2022526298A/en active Pending
- 2020-03-19 SG SG11202110164YA patent/SG11202110164YA/en unknown
- 2020-03-19 CA CA3133989A patent/CA3133989A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2022526298A (en) | 2022-05-24 |
EP3941487B1 (en) | 2024-02-14 |
TW202043465A (en) | 2020-12-01 |
KR20210141599A (en) | 2021-11-23 |
CN113727721A (en) | 2021-11-30 |
DE102019108125B4 (en) | 2022-02-03 |
AU2020241411A1 (en) | 2021-10-28 |
CA3133989A1 (en) | 2020-09-24 |
EP3941487A1 (en) | 2022-01-26 |
DE102019108125A1 (en) | 2020-10-01 |
MX2021011375A (en) | 2021-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3874030A4 (en) | Compositions and methods for t cell engineering | |
EP3546570A4 (en) | Serum-free immune cell-culturing medium-added kit, method for culturing immune cells by using same kit, serum-free immune cell culture obtained by same kit or culturing method, and cosmetic composition comprising same culture | |
EP3638777A4 (en) | Compositions and methods for increasing the efficiency of cell cultures used for food production | |
EP3571230A4 (en) | Compositions and methods for the depletion of cd137+ cells | |
EP3700540A4 (en) | Compositions and methods for the depletion of cd117+ cells | |
EP3700568A4 (en) | Compositions and methods for the depletion of cd117+ cells | |
EP3284816A4 (en) | Culture medium additive, culture medium composition, and method for culturing cells or tissue using same | |
EP3966316A4 (en) | Modified pluripotent cells | |
EP3697820A4 (en) | Methods and compositions relating to engineered regulatory t cells | |
IL290080A (en) | Nk cell composition and preparations for immunotherapy and methods for their production | |
EP3733834A4 (en) | Scaffolding material for stem cell cultures and stem cell culture method using same | |
IL286776A (en) | Compositions and methods for preparing t cell compositions and uses thereof | |
IL288260A (en) | Compositions and methods for plant cell culture | |
EP4295914A3 (en) | Genetically-engineered drug resistant t cells and methods of using the same | |
IL290590A (en) | Cell culture methods | |
MX2022001428A (en) | Methods and compositions for culturing hemoglobin-dependent bacteria. | |
EP3999078A4 (en) | Methods for culturing mesenchymal stem cells, products thereof, and applications thereof | |
IL281231A (en) | Methods of continuous cell culture | |
EP3967753A4 (en) | Method for culturing allogeneic immune cell, immune cell culture obtained thereby, and immune cell therapeutic agent comprising same | |
EP3315601A4 (en) | Method for culturing animal cell composition, method for producing animal cell composition using same, and animal cell composition | |
SG11202110164YA (en) | Cd28 t cell cultures, compositions, and methods of using thereof | |
EP3561051A4 (en) | Composition for promoting proliferation of pluripotent stem cells, and method for promoting proliferation of pluripotent stem cells | |
IL288819A (en) | Cell culture methods and compositions for antibody production | |
IL288301A (en) | Methods of culturing human pluripotent cells | |
EP4063491A4 (en) | Composition for culturing natural killer cells and method for preparing natural killer cells by using same |